부산대학교 도서관

Keywords: Aducanumab; Bapineuzumab; Donanemab; Lecanemab EN Aducanumab Bapineuzumab Donanemab Lecanemab 1 3 3 09/27/23 20230925 NES 230925 Alzheimer's disease (AD) was described over a century ago as a disease of dementia with the presence of amyloid and tau pathologies [[1]], but the past year has seen the first clear evidence that effective disease-modifying anti-amyloid antibody (AAA) therapies are possible. The side effect profile included local injection reactions and ARIA (amyloid-related imaging abnormalities) that could be classified as either ARIA-E (for edema) or ARIA-H (for hemorrhage). Abbreviations AAA Anti-amyloid antibody ARIA-E Amyloid-related imaging abnormality-edema ARIA-H Amyloid-related imaging abnormality-hemorrhage APOE Apolipoprotein E ASO Antisense oligonucleotide Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. [Extracted from the article]